#1 Clinical Trials Search in Europe

Autologous Cd34+Enriched Cells From Patients With Fanconi Anemia Subtype A Transduced Ex Vivo With Lentiviral Vector Carrying The Fanconi Anemia Complementation Group A Gene

Clinical trials are underway to evaluate the long-term safety and effectiveness of a novel gene therapy approach for patients with Fanconi Anemia Subtype A (FA-A). This therapy, known as RP-L102, involves using the patient’s own blood-forming stem cells, which are genetically modified to carry a corrected version of the FANCA gene. These trials aim to assess the potential of this treatment to improve blood cell production and reduce the risk of bone marrow failure and cancer in FA-A patients over an extended period.

Table of Contents

What is Fancalen?

Fancalen, also known as RP-L102, is an innovative gene therapy product designed to treat Fanconi anemia subtype A (FA-A)[1]. It is classified as an advanced therapy medicinal product, specifically a gene therapy[2]. Fancalen is made from a patient’s own cells, which are modified to carry a corrected version of the faulty gene responsible for FA-A.

How Does Fancalen Work?

Fancalen works by using a process called ex vivo gene therapy. Here’s a simplified explanation of how it works:

  1. Doctors collect CD34+ cells from the patient’s blood or bone marrow. These are a type of stem cell that can develop into various blood cell types.
  2. In a laboratory, these cells are modified using a lentiviral vector (a type of virus that has been changed to be safe for medical use). This vector carries a correct copy of the FANCA gene, which is faulty in patients with FA-A.
  3. The modified cells, now containing the correct FANCA gene, are then given back to the patient through an intravenous infusion (a drip into a vein)[1][2].

The goal is for these modified cells to produce healthy blood cells that carry the correct FANCA gene, potentially improving the patient’s condition.

What Condition Does Fancalen Treat?

Fancalen is specifically designed to treat Fanconi anemia subtype A (FA-A)[1]. Fanconi anemia is a rare genetic disorder that affects bone marrow function and can lead to various health problems. People with FA-A have a faulty FANCA gene, which causes their cells to have difficulty repairing DNA damage. This can result in:

  • Bone marrow failure: The bone marrow doesn’t produce enough blood cells.
  • Increased risk of blood cancers like leukemia.
  • Higher likelihood of developing other types of cancers, especially of the head and neck.
  • Various physical abnormalities that can affect different parts of the body.

Clinical Trials and Research

Fancalen is currently being studied in clinical trials to evaluate its safety and effectiveness. These trials include:

  • Phase I/II studies to assess the initial safety and potential benefits of Fancalen[1][2].
  • Long-term follow-up studies to monitor patients who have received Fancalen for extended periods, sometimes up to 15 years after treatment[2].

Safety and Efficacy

The ongoing clinical trials are designed to evaluate several aspects of Fancalen’s safety and efficacy:

  • Long-term safety: Researchers are closely monitoring patients for any side effects or complications that may arise from the gene therapy[1][2].
  • Persistence of the corrected gene: Studies are checking how long the modified cells containing the correct FANCA gene remain in the patient’s body and continue to function[1].
  • Blood cell production: Researchers are assessing whether Fancalen leads to improved and stable blood cell counts over time[1][2].
  • Resistance to DNA damage: Tests are being conducted to see if the treated cells show improved ability to resist DNA-damaging agents, which is a key problem in Fanconi anemia[1][2].

Long-Term Follow-Up

Patients who receive Fancalen are closely monitored for extended periods. This long-term follow-up includes:

  • Regular check-ups and blood tests to assess overall health and blood cell counts.
  • Monitoring for any signs of bone marrow failure or development of cancers.
  • Assessments of quality of life and overall well-being[2].

Potential Benefits

If successful, Fancalen could offer several potential benefits for patients with FA-A:

  • Improved bone marrow function and blood cell production.
  • Reduced risk of bone marrow failure and need for bone marrow transplantation.
  • Potentially lower risk of developing blood cancers and other FA-related cancers.
  • Improved overall quality of life and life expectancy.

Considerations and Risks

While Fancalen shows promise, it’s important to understand that it is still an experimental treatment. Potential risks and considerations include:

  • Possible side effects from the gene therapy process.
  • Uncertainty about long-term effects, as this is a relatively new treatment approach.
  • The need for ongoing monitoring and follow-up care.
  • Possibility that the treatment may not be effective for all patients.

As research continues, more information about the effectiveness and long-term safety of Fancalen will become available. Patients and families considering this treatment should discuss all options, potential benefits, and risks with their healthcare providers.

Aspect Details
Treatment RP-L102 (Fancalen): Autologous CD34+ cells genetically modified with FANCA gene
Condition Fanconi Anemia Subtype A (FA-A)
Study Type Long-term follow-up of Phase I/II clinical trials
Duration Up to 15 years post-infusion
Primary Objectives Evaluate long-term safety, gene persistence, blood count stability, phenotypic correction
Key Assessments Blood counts, gene presence in blood/bone marrow, integration site analysis, cancer monitoring
Eligibility Patients who received RP-L102 in previous clinical trials
Administration Intravenous infusion

FAQ

  • What is RP-L102 and how does it work? RP-L102 is a gene therapy product containing the patient's own CD34+ blood-forming stem cells that have been genetically modified. These cells are altered using a lentiviral vector to carry a healthy copy of the FANCA gene, which is defective in Fanconi Anemia Subtype A patients. The modified cells are then infused back into the patient, aiming to produce healthy blood cells and improve bone marrow function.
  • How long will patients be followed in these clinical trials? Patients will be followed for up to 15 years after receiving the RP-L102 infusion. This long-term follow-up is crucial to assess the safety and effectiveness of the treatment over time.
  • What are the main objectives of these long-term follow-up studies? The main objectives include evaluating long-term safety, determining the persistence of the corrected gene in blood and bone marrow cells, assessing blood count stability, monitoring for potential development of cancers, and evaluating the correction of cellular defects characteristic of Fanconi Anemia.
  • What kind of assessments will be performed during the follow-up? Assessments will include regular blood tests to check blood cell counts and the presence of the corrected gene, bone marrow evaluations, monitoring for any adverse events or development of cancers, and tests to check if the treated cells are resistant to DNA-damaging agents (which is a characteristic of healthy cells in people without Fanconi Anemia).
  • Who is eligible to participate in these long-term follow-up studies? Patients who were previously enrolled in the initial RP-L102 clinical trials and received the gene therapy infusion are eligible for these long-term follow-up studies. They must be willing to adhere to the study schedule and provide informed consent.

Ongoing Clinical Trials on Autologous Cd34+Enriched Cells From Patients With Fanconi Anemia Subtype A Transduced Ex Vivo With Lentiviral Vector Carrying The Fanconi Anemia Complementation Group A Gene

  • Study on the Safety and Effects of Infusing Modified CD34+ Cells for Patients with Fanconi Anemia Subtype A

    Recruiting

    1 1
    Investigated drugs:
    Spain

  • Long-Term Study on the Safety and Effects of RP-L102 Infusion for Patients with Fanconi Anemia Subtype A

    Recruiting

    1 1
    Investigated drugs:
    Spain

Glossary

  • Fanconi Anemia Subtype A (FA-A): A rare genetic disorder that affects bone marrow function, leading to decreased production of blood cells. It is caused by mutations in the FANCA gene.
  • CD34+ cells: A type of blood-forming stem cell found in bone marrow that can develop into all types of blood cells.
  • Lentiviral vector: A tool used in gene therapy to deliver genetic material into cells. It is derived from a type of virus but modified to be safe for therapeutic use.
  • FANCA gene: The gene that, when mutated, causes Fanconi Anemia Subtype A. The healthy version of this gene is used in the RP-L102 therapy.
  • Bone marrow failure: A condition where the bone marrow doesn't produce enough healthy blood cells.
  • Hematologic malignancy: Cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia or lymphoma.
  • Provirus: The genetic material of a virus that is integrated into the DNA of a host cell. In this context, it refers to the therapeutic gene integrated into the patient's cells.
  • Replication-competent lentivirus (RCL): A potential safety concern in gene therapy where the viral vector used could theoretically regain the ability to replicate and spread.
  • Phenotypic correction: The restoration of normal cellular function in cells that previously had a genetic defect.
  • Integration site analysis (ISA): A method to determine where the therapeutic gene has integrated into the patient's DNA.

References

  1. http://clinicaltrials.eu/trial/long-term-study-on-the-safety-and-effects-of-rp-l102-infusion-for-patients-with-fanconi-anemia-subtype-a/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-infusing-modified-cd34-cells-for-patients-with-fanconi-anemia-subtype-a/